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Introduction
The survival of multiple myeloma patients has improved 
over the last two decades with the introduction of new 
drugs [1, 2]. In addition, the concept of combined thera-
pies has evolved in pursuit of synergistic effects [3]. 
Although new treatment options have led to improved 
survival, multiple myeloma remains an incurable malignant 
disease and an important challenge is to apply data from 
clinical trials to the real- life population of multiple myeloma 
[4].
The incidence of multiple myeloma increases with age 
and the prolonged survival of the population in general 
will lead to an increased number of multiple myeloma 
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Abstract
To describe the prevalence of comorbidity and its impact on survival in newly 
diagnosed multiple myeloma patients compared with population controls. Cases 
of newly diagnosed symptomatic multiple myeloma during the 2005–2012 period 
were identified in the Danish National Multiple Myeloma Registry. For each 
myeloma patient, 10 members of the general population matched by age and 
sex were chosen from the national Civil Registration System. Data on comor-
bidity in the myeloma patients and the general population comparison cohort 
were collected by linkage to the Danish National Patient Registry (DNPR). Cox 
proportional hazards regression models were used to evaluate the prognostic 
significance of comorbidity. The study included 2190 cases of multiple myeloma 
and 21,900 population controls. The comorbidity was increased in multiple 
myeloma patients compared with population controls, odds ratio (OR) 1.4 
(1.1–1.7). The registration of comorbidity was highly increased within the year 
preceding diagnosis of multiple myeloma (OR 3.0 [2.5–3.5]), which was at-
tributable to an increased registration of various diseases, in particular, renal 
disease with OR 11.0 (8.1–14.9). The median follow- up time from diagnosis of 
multiple myeloma for patients alive was 4.3 years (interquartile range 2.4–6.3). 
Patients with registered comorbidity had increased mortality compared with 
patients without comorbidity, hazard ratio 1.6 (1.5–1.8). Multiple myeloma pa-
tients have increased comorbidity compared with the background population, 
in particular during the year preceding the diagnosis of myeloma.
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patients in the future [5]. Comorbidities correlate with 
aging and make the elderly particularly vulnerable to tox-
icities of therapy. A key issue is therefore to choose the 
optimal therapy for these patients [6]. An increasing 
awareness of the vulnerability of the elderly has lead to 
recommendations for dose adjustment of treatment in 
patients with comorbid conditions [7]. Recently, a frailty 
score was proposed by the International Myeloma Working 
Group including age, geriatric assessment, and comorbidity 
assessed by the Charlson Comorbidity Index [8]. This 
scoring system was based on data from three prospective 
clinical trials and predicts mortality and the risk of toxic-
ity in myeloma patients. However, patients with comor-
bidities are often excluded from clinical trials and therefore 
these data may not necessarily provide guidance for treat-
ment decisions for the elderly patients in general. Data 
on the prevalence and impact of comorbidity in the real- 
life population of multiple myeloma patients is limited 
[5, 9].
We therefore conducted a population- based Danish 
study of all patients with newly diagnosed multiple myeloma 
and a matched control population to compare the burden 
of comorbidity and to evaluate the impact of comorbidity 
on mortality.
Materials and Methods
Denmark has approximately 5.6 million inhabitants and 
every resident is registered in the national Civil Registration 
System (CRS), and is assigned a personal identification 
number (the CPR- number) at birth, which allows linkage 
between demographic and medical registries [10]. The 
National Health Service provides tax- supported health care 
for all citizens in Denmark and guarantees free access to 
hospitals.
Study population
The Danish Multiple Myeloma Registry was established 
in 2005 by the Danish Myeloma Study Group (DMSG) 
[11]. Danish hematology departments are obligated to 
report all incident cases of multiple myeloma, solitary 
plasmacytoma, MGUS, and plasma cell leukemia to the 
registry. The database include the date of myeloma diag-
nosis, percentage of plasma cells in the bone marrow, 
result of skeletal X- ray, ECOG performance status, clinical 
presentation, for example, spinal cord compression, type 
and concentration of the M- component, and basic bio-
chemical parameters, for example, beta- 2- microglobulin. 
In the study period, the 2003 criteria for classification of 
monoclonal gammopathies from the International 
Myeloma Working Group were used [12]. Annual links 
to the Danish National Patient Registry ensure that cases 
of multiple myeloma that have not been reported to the 
Danish Multiple Myeloma Registry are subsequently 
included. A recent validation of the registry has shown 
almost 100% completeness [11].
Data on comorbidity
The Danish National Patient Registry (DNPR) has, since 
1977, routinely collected nationwide data on all nonpsy-
chiatric hospitalizations, and since 1995, visits to emergency 
departments and outpatient clinics have also been included 
[13]. The DNRP records CPR- number and date of each 
hospital visit, together with primary and secondary dis-
charge diagnoses. The DNPR has almost complete coverage 
of national hospital admissions [14]. Data have been coded 
according to the International Classification of Diseases, 
10th revision (ICD- 10) since 1994.
Comorbidity was classified according to the 19 diseases 
included in the Charlson Comorbidity Index (CCI) [15]. 
We computed a CCI score based on registered diagnoses 
within 10 years and until 1 month before diagnosis of 
multiple myeloma. Four levels of comorbidity were defined: 
0 (“low”) for individuals with no recorded underlying 
diseases included in the CCI; 1 (“moderate low”), 2 
(“moderate high”), and ≥3 (“high”).
General population comparison cohort
For each myeloma patient, we randomly chose 10 members 
of the general population from the CRS, matched by year 
of birth and sex. The members of the comparison cohort 
had to be alive with no diagnosis of multiple myeloma 
on the date when follow- up of the matched myeloma 
patient began. Thus, the control persons were included 
at the time of diagnosis of their corresponding multiple 
myeloma patient with whom they were matched. Data 
on comorbidity was obtained from the DNPR.
Statistical analysis
Comparisons of binary variables were conducted by chi- 
square test or Fisher’s exact test, mid- P approach [16]. 
Continuous variables were presented using medians with 
range or interquartile range. Ordinal variables were com-
pared using Mann–Whitney test. Overall survival was 
defined as the time from diagnosis to death from any 
cause and was described using the Kaplan–Meier method. 
Comorbidity was assessed for two different time periods, 
namely from 1 year until 1 month before diagnosis of 
multiple myeloma and from 10 years until 1 month before 
diagnosis of multiple myeloma. Cox proportional hazards 
regression models were performed to evaluate the prog-
nostic significance of comorbidity and the results are 
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presented as estimated hazard ratios (HRs) with 95% 
confidence intervals. The proportionality assumptions for 
the models were assessed by scaled Schoenfeld residuals 
and we did not find violations of the assumptions. When 
comparing subgroups with few events, a permutation 
method was used for calculating P- values [17]. R function 
“permlogrank” in the “clinfun” package was used for these 
calculations. The interaction between myeloma and comor-
bidities on mortality was inspected by calculating an 
interaction contrast on an additive scale. The age/gender 
standardized mortality rate differences between multiple 
myeloma and population controls for each level of comor-
bidity were calculated and compared to the difference in 
multiple myeloma/population controls without comorbidi-
ties [18]. For calculations of nonlinear effects on survival 
of age, a general additive model was performed with age 
as a smoothing spline with four degrees of freedom. All 
tests were two- sided and P- values of 0.05 were considered 
statistically significant. All confidence intervals are 95% 
and two- sided. Data analyses were performed using R 
version 3.2.3 (R Foundation for Statistical Computing, 
Vienna, Austria).
The study was approved by the Danish Data Protection 
Agency (No. 2008- 58- 0028).
Results
The study included a total of 2190 patients with symp-
tomatic multiple myeloma in the period 2005–2012 in 
Denmark. The median age at diagnosis was 70 years (range 
30–98 years), and 1204 (55%) were men. The median 
duration of follow- up for patients alive was 4.3 years 
(interquartile range 2.4–6.3). Characteristics of the patients 
and population controls are described in Table 1.
Comorbidity in the myeloma cohort and 
population controls
Comorbidity at cohort entry was registered in 40.9% of 
the patients. The overall comorbidity was increased in 
multiple myeloma patients compared with population 
controls, odds ratio (OR) 1.4 (1.1–1.7). The prevalence 
of comorbidity was higher in patients over 65 years of 
age compared with the younger patients, for example, 
Table 1. Characteristics of 2190 Danish patients with newly diagnosed symptomatic multiple myeloma and 21,900 matched population controls.
Myeloma patients Population controls
Total 2190 21,900
Gender, n (%) Male 1204 (55%) 12,040 (55%)
Age (years) Median (min, max) 70 (19 – 98) 70 (19–98)
Age >65 years, n (%) 1425 (65%) 14,250 (65%)
M- component, n (%) IgA 443 (20.8%) –
IgG 1184 (55.5%) –
IgM 11 (0.5%) –
Free light chain 339 (15.9%) –
Other1 156 (7.4%) –
Missing 57 
International staging system, n (%) I 497 (27.4%) –
II 651 (36.7%) –
III 639 (34.9%) –
Missing 403
WHO performance status, n (%) 0 502 (23.0%) –
1 888 (40.8%)
2 442 (20.3%) –
≥3 347 (15.9%) –
Missing 11
LDH, increased, n (%) 463 (22.2%)
Missing 104
CRP, increased, n (%) 809 (38.6%)
Missing 92
Creatinine, increased, n (%) 770 (35.6%)
Missing 27
Comorbidity score2 0 1294 (59.1%) 14250 (65.1%)
1 317 (14.5%) 3278 (15.0%)
2 306 (14.0%) 2403 (11.0%)
≥3 273 (12.5%) 1969 (9.0%)
1Biclonal and nonsecretory myeloma.
2Comorbidity classified according to Charlson Comorbidity Index (P < 0.0001).
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three or more comorbidities in 226 (15.9%) patients 
>65 years versus 47 (6.1%) patients ≤65 years (P < 0.0001). 
In addition, comorbidity was higher in male patients 
(42.3%) compared with female patients (39.3%) 
(P = 0.04). Table 2 describes details on registration of 
the diseases in the Charlson Comorbidity Index. The reg-
istration of comorbidity was highly increased within the 
year preceding diagnosis of multiple myeloma (OR 3.0 
[2.5–3.5; P < 0.0001]) which was attributable to an increased 
registration of various diseases, in particular, renal disease 
with OR 11.0 (8.1–14.9) (Table 2). By contrast, comor-
bidity was not increased in the time period from 10 years 
until 1 year before diagnosis of multiple myeloma (OR 
1.0 [0.9–1.1, P = 0.77]) and the only deviations of indi-
vidual diseases in this time period were an increased 
prevalence of renal disease (OR 1.5 [1.1–2.1; P = 0.02]) 
and lower prevalence of dementia (OR 0.3 [0.2–0.6; 
P = 0.0001]). An increased registration of venous throm-
boembolism was observed in the period from 10 years 
until diagnosis of multiple myeloma and in the year pre-
ceding the diagnosis of multiple myeloma with OR of 
1.5 (1.1–1.9; P = 0.003) and 2.8 (1.6–4.5; P = 0.0004), 
respectively.
Survival in the multiple myeloma cohort
The median overall survival in all patients was 3.3 years 
(1.0–6.5) comprising median survival of 5.7 years (2.5 
– not reached) and 2.3 years (0.6–4.7) in patients aged 
65 years or younger and in patients older than 65 years, 
respectively. Figure 1 shows the survival stratified 
according to the Charlson Comorbidity Index for 
Table 2. Hazard ratios comparing the individual diseases included in the Charlson Comorbidity Index in 2190 Danish patients with newly diagnosed 
symptomatic multiple myeloma and 21,900 population controls.
Diagnosis Registered comorbidity from 10 years until 1 month before 
diagnosis of multiple myeloma
Registered comorbidity from 1 year until 1 month before 
diagnosis of multiple myeloma
Number (%) OR (95% CI) P Number (%) OR (95% CI) P
Any Charlson 
condition
896 (40.9%) 1.4 (1.1–1.7) <0.0001 194 (8.9%) 3.0 (2.5–3.5) <0.0001
Myocardial 
infarction
118 (5.4%) 1.1 (0.9–1.3) 0.5745 18 (0.8%) 1.7 (1.0–2.7) 0.0557
Congestive heart 
failure
126 (5.8%) 1.4 (1.1–1.7) 0.0016 36 (1.6%) 2.8 (1.9–4.0) <0.0001
Peripheral vascular 
disease
82 (3.7%) 0.9 (0.7–1.1) 0.3126 16 (0.7%) 1.2 (0.7–1.9) 0.5429
Cerebrovascular 
disease
160 (7.3%) 0.9 (0.7–1.0) 0.1390 29 (1.3%) 1.3 (0.9–1.9) 0.2181
Dementia 17 (0.8%) 0.5 (0.3–0.8) 0.0015 8 (0.4%) 1.1 (0.5–2.1) 0.8539
Chronic pulmonary 
disease
147 (6.7%) 1.0 (0.8–1.2) 0.9526 28 (1.3%) 1.7 (1.1–2.5) 0.0140
Connective tissue 
disease
72 (3.3%) 1.2 (0.9–1.5) 0.2264 19 (0.9%) 3.9 (2.2–6.6) <0.0001
Ulcer disease 89 (4.1%) 1.6 (1.3–2.0) 0.0002 33 (1.5%) 5.3 (3.4–8.1) <0.0001
Mild liver disease 17 (0.8%) 1.2 (0.7–2.0) 0.4267 6 (0.3%) 3.2 (1.2–7.7) 0.0276
Diabetes Mellitus 71 (3.2%) 1.0 (0.8–1.3) 0.7061 12 (0.5%) 1.6 (0.8–2.8) 0.1664
Hemiplegia 7 (0.3%) 1.3 (0.6–2.8) 0.4779 1 (0.0%) 2.2 (0.1–14.5) 0.5324
Moderate and 
severe renal 
disease
131 (6.0%) 3.7 (3.0–4.6) <0.0001 89 (4.1%) 11.0 (8.1–14.9) <0.0001
Diabetes mellitus 
with chronic 
complications
73 (3.3%) 1.1 (0.9–1.4) 0.3096 18 (0.8%) 2.3 (1.3–3.7) 0.0042
Any tumor 223 (10.2%) 1.2 (1.0–1.4) 0.0149 49 (2.2%) 1.9 (1.3–2.5) 0.0003
Leukemia 8 (0.4%) 1.1 (0.5–2.1) 0.8539 2 (0.1%) 1.6 (0.2–6.0) 0.5517
Lymphoma 21 (1.0%) 2.0 (1.2–3.2) 0.0069 8 (0.4%) 5.8 (2.3–13.6) 0.001
Moderate and 
severe Liver 
disease
2 (0.1%) 0.5 (0.1–1.7) 0.3254 1 (0.0%) 1.9 (0.1–11.3) 0.6145
Metastatic solid 
tumor
41 (1.9%) 1.9 (1.3–2.6) 0.0006 25 (1.1%) 4.1 (2.6–6.5) <0.0001
AIDS 0 (0.0%) – 0.62 0 (0.0%) – –
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myeloma patients and population controls. Patients 
with any registered comorbidity had increased mortality 
compared with patients without comorbidity, HR 1.6 
(1.5–1.8). The mortality according to the diseases that 
constitute the Charlson Comorbidity Index is shown 
in Table 3. Registration of venous thromboembolism 
was associated with increased mortality (HR 2.0 [1.5–2.7; 
P < 0.0001]).
Risk factors for survival
A Cox proportional hazards model was used to analyze 
the impact on mortality of comorbidity and well- known 
risk factors, including age, International Staging System, 
serum lactate dehydrogenase, serum creatinine, serum 
C- reactive protein, IgA M- component, and WHO per-
formance status (0–1 vs. 2–4) (Table 4). The mortality 
was increased in patients registered with comorbidity 
according to Charlson Comorbidity Index compared 
with patients without registered comorbidity, for example, 
hazard ratios of 1 (ref), 1.5 (1.2–1.8), 1.3 (1.0–1.5), 
and 1.7 (1.4–2.1) in the comorbidity groups 0, 1, 2, 
and ≥3, respectively. A division of comorbidity into 
two groups similar to the International Myeloma Working 
Group (IMWG) frailty study (CCI <2 vs. CCI ≥2) showed 
an increased mortality in the group with high comor-
bidity (HR 1.3 [1.1–1.5; P = 0.0003]) [8]. Three 
sensitivity analyses on the association between OS and 
comorbidities were performed. The analyses were (1) 
using CCI excluding renal disease, (2) using CCI exclud-
ing comorbidities with onset less than a year before 
multiple myeloma diagnosis, and (3) including age as 
a continuous nonlinear covariate. All models showed 
comparable effect of comorbidities on overall survival 
(data not shown).
Comorbidity and WHO performance status
There was no association between Charlson Comorbidity 
Index and the WHO performance status at time of diag-
nosis of multiple myeloma (p = 0.07, chi- square test) 
(Table 5).
High- dose melphalan with hematopoietic 
stem cell support
High- dose melphalan with haematopoietic stem cell sup-
port (HDT) was used as first- line therapy in 582 (76.1%) 
patients 65 years or younger, and in 103 (7.2%) patients 
older than 65 years. Comorbidity affected the utilization 
of HDT, for example, used in 452 (81.1%) patients 65 years 
or younger with no registered comorbidity in contrast to 
24 (51.1%) patients with three or more comorbidities 
(Table 6).
Figure 1. Survival according to Charlson comorbidity score for 2190 patients with newly diagnosed symptomatic multiple myeloma (MM) and 21,900 
population controls in Denmark during the period 2005–2012.
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Discussion
In this large nationwide cohort study, we found an increased 
comorbidity in patients with multiple myeloma at time 
of diagnosis compared to population controls. This increase 
in comorbidity was mainly confined to the year proceed-
ing diagnosis of myeloma. In both younger and elderly 
Table 3. Mortality according to comorbidities used in the Charlson Comorbidity Index in 2190 Danish newly diagnosed symptomatic multiple 
 myeloma patients.
Diagnosis 5- year survival Hazard ratio 95% CI P
Any Charlson condition 23% 1.6 1.5–1.8 <0.0001
Myocardial infarction 22% 1.6 1.3–2.1 <0.0001
Congestive heart failure 20% 1.8 1.5–2.2 <0.0001
Peripheral vascular disease 12% 1.6 1.2–2.1 0.0005
Cerebrovascular disease 20% 1.6 1.3–1.9 <0.0001
Dementia 0% 2.8 1.7–4.8 0.0004
Chronic pulmonary disease 16% 1.7 1.4–2.1 <0.0001
Connective tissue disease 30% 1.2 0.9–1.6 0.16
Ulcer disease 13% 1.8 1.4–2.3 <0.0001
Mild liver disease 0% 1.8 1.0–3.1 0.04
Diabetes mellitus 17% 1.5 1.1–2.0 0.010
Hemiplegia1 19% – – 0.90
Moderate and severe renal 
disease
24% 1.6 1.2–1.9 <0.0001
Diabetes mellitus with 
chronic complications
18% 1.5 1.2–2.1 0.003
Any tumor 26% 1.2 1.0–1.4 0.06
Leukemia1 44% – – 0.90
Lymphoma 25% 1.2 0.7–2.0 0.55
Moderate and severe 
Liver disease1
50% – – 0.71
Metastatic solid tumor 22% 1.2 0.8–1.7 0.35
The Hazard ratios were based on comparisons with patients without the particular comorbidity. The analysis included registered comorbidity from 
10 years until 1 month before diagnosis of multiple myeloma. Survival was defined as the time from diagnosis of multiple myeloma to death from any 
cause.
1For uncommon comorbidities (n < 10), no Hazard ratios were calculated and P- values were calculated using Monte Carlo method. No multiple 
myeloma patients had AIDS and this condition was excluded from the table.
Table 4. Multivariate analysis of prognostic factors on survival in 2190 Danish patients with newly diagnosed symptomatic multiple myeloma.
Variable Univariate analysis Multivariable analysis
Hazard ratio (95% CI) Hazard ratio (95% CI)
Charlson Comorbidity Index
0 1 (ref) 1 (ref)
1 1.7 (1.5–2.0) 1.5 (1.2–1.8)
2 1.3 (1.1–1.5) 1.3 (1.0–1.5)
≥3 2.0 (1.7–2.4) 1.7 (1.4–2.1)
Age (>65 years) 2.5 (2.2–2.9) 2.2 (1.9–2.6)
Gender (male) 1.0 (0.9–1.1) –
International staging system (ISS)
1 1 (ref) 1 (ref)
2 1.8 (1.5–2.2) 1.6 (1.3–1.9)
3 2.9 (2.4–3.4) 1.9 (1.6–2.4)
Increased serum lactate dehydrogenase level 1.5 (1.3–1.7) 1.3 (1.1–1.5)
Increased serum creatinine level 1.8 (1.6–2.0) 1.2 (1.0–1.4)
Increased serum C- reactive protein level 1.6 (1.5–1.8) 1.2 (1.1–1.4)
IgA M- component 1.2 (1.0–1.4) 1.3 (1.1–1.5)
WHO Performance status (0–1 vs. 2–4) 2.0 (1.8–2.2) 1.7 (1.5–2.0)
Comorbidity assessed by Charlson Comorbidity Index based on diagnoses registered from 10 years to 1 month prior to myeloma diagnosis in the 
Danish National Patient Registry.
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myeloma patients, comorbidity was associated with 
increased mortality.
The prevalence of comorbid diseases in our study is 
in accordance with the observations in a Swedish 
population- based study based on the Swedish Cancer 
Registry where comorbidity was seen in approximately 
40% of the multiple myeloma patients and with an 
Italian study based on a regional multiple myeloma 
registry [9, 19]. We provide a further extension of the 
importance of comorbidity by comparing comorbidity 
in multiple myeloma patients with population controls 
and we found an increased registration of various 
comorbidities in multiple myeloma patients, in particular 
renal disease. This finding is consistent with studies 
on solid cancers that observed an increased comorbidity 
compared to the background population at diagnosis 
in specific cancers, for example, in lung and colorectal 
cancer patients [8, 20]. In our study, the increased 
comorbidity was mainly caused by an increased regis-
tration of comorbid diseases within the last year pre-
ceding the diagnosis of multiple myeloma. Several factors 
may be important and involved in this observation. 
Well- known multiple myeloma complications and mor-
bidity secondary to multiple myeloma may partly explain 
the increased frequency, for example, the increased risk 
of myocardial infarction within the first years might 
reflect the increased risk of thromboembolism observed 
in multiple myeloma [21]. This is supported by the 
fact that we found the same pattern for venous 
thromboembolism in our study cohort. The high preva-
lence of renal disease compared to the population con-
trols is plausible and reflects that renal impairment is 
a frequent complication in multiple myeloma [22]. In 
addition, our cohort will have included cases of mono-
clonal gammopathy of renal significance (MGRS) that 
later underwent malignant transformation to multiple 
myeloma [23, 24]. An essential issue is the distinction 
between multiple myeloma complications and true 
comorbidity. A considerable part of the registered 
comorbidity within the last year prior to diagnosis might 
be related to the diagnostic process rather than reflect-
ing true comorbidity in multiple myeloma. In a few 
cases, it might reflect the detection of multiple myeloma 
in patients in diagnostic workup for unrelated diseases 
which are subsequently registered as part of the comor-
bidity. However, symptomatic multiple myeloma is not 
likely to pass undetected for longer periods of time 
due to the prominent symptomatology. The association 
between registration of comorbidity and time to diag-
nosis of multiple myeloma raises methodological issues 
regarding when to assess comorbidity in studies on 
multiple myeloma.
We found that comorbidity increased the mortality 
in multiple myeloma patients. There was no clear dif-
ference in mortality between the subgroups 1, 2, and 
≥3 according to Charlson Comorbidity Index. However, 
differences in mortality were observed when comorbidity 
according to Charlson Comorbidity Index was used as 
Table 5. Association between comorbidity and WHO performance status in 2190 Danish patients with newly diagnosed symptomatic multiple 
myeloma.
Charlson comorbidity Index WHO performance status 0–1 WHO performance status 2–4
0 838 (65.0%) 451 (35.0%)
1 191 (60.6%) 124 (39.4%)
2 204 (66.9%) 101 (33.1%)
3 157 (58.1%) 113 (41.9%)
P = 0.07 (chi- square test). Numbers do not add up to 2190 due to missing data on WHO performance status.
Table 6. Use of treatment with high- dose melphalan with stem cell support (HDT) according to comorbidity in 2190 Danish patients with newly di-
agnosed symptomatic multiple myeloma.
Comorbidity All patients Patients age ≤65 years
HDT Other treatment HDT Other treatment
0 521 (76.1%) 773 (51.4%) 452 (77.7%) 105 (57.4%)
1 64 (9.3%) 253 (16.8%) 49 (8.4%) 28 (15.3%)
2 73 (10.7%) 233 (15.9%) 58 (10.0%) 26 (14.2%)
≥3 27 (3.9%) 246 (16.3%) 23 (4.0%) 24 (13.1)
P1 <0.0001 <0.0001
Comorbidity according to Charlson Comorbidity index. Chi- square test. HDT: intention- to- treat.
1HDT versus no HDT for all patients and for patients with age ≤65 years.
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dichotomous variables, for example, between patients 
with no registered comorbidity and patients with any 
grade of comorbidity, or between patients with comor-
bidity score less than 2 compared with patients with a 
score of 2 or higher. The HR of 1.3 in this later division 
is in accordance with the HR of 1.37 found in the IMWG 
frailty study by Palumbo et al. [8]. This frailty score is 
based on data from clinical trials and due to study exclu-
sion criteria, the pattern of comorbidity is likely to be 
different from that of unselected myeloma patients in 
a population- based study. Thus, our study provides sup-
port for the comorbidity element of the IMWG frailty 
score also being valid in a population- based setting. 
However, there is a need for studies that validate the 
frailty score and address comorbidity in population- based 
settings.
Charlson Comorbidity Index creates a pooled estimate 
of comorbidity and assigns particular weights to a num-
ber of diseases [15]. It was developed almost 30 years 
ago to predict mortality in medical patients admitted 
to hospitals and has been shown to be robust in a 
number of clinical settings, including validated for several 
different cancers and it is the most extensively studied 
comorbidity index for predicting mortality. However, 
the prognosis of the individual included diseases has 
changed over time, for example, the prognosis of AIDS 
has considerably changed since the eighties and some 
of the comorbidities are rarely detected in myeloma 
patient, for example, dementia and AIDS. In addition, 
the Charlson Comorbidity Index only includes limited 
information on disease severity. A recent study indicates 
that the Freiburg comorbidity index which is based on 
performance status, renal impairment, and lung disease 
might be more useful than the Charlson Comorbidity 
Index in predicting overall survival in elderly patients 
with multiple myeloma [25].
The adverse prognostic impact of comorbidity on sur-
vival is complex. Comorbidities may independently increase 
the risk of death or might add to well- known myeloma 
risk factors, for example, further increase the risk of seri-
ous infections or venous thromboembolic disease. In addi-
tion, comorbidity may indirectly affect the prognosis by 
affecting the choice of myeloma treatment and lead to 
more frequent dose reduction [26]. Our data confirm 
how a high burden of comorbidity reduces the use of 
HDT in younger myeloma patients. Our study design did 
not permit an evaluation of the association between comor-
bidity and the use of other myeloma treatment and dose 
reductions.
The main strength of our study is its large size with 
inclusion of all newly diagnosed multiple myeloma patients 
in a population- based setting and the use of a population 
comparison cohort. The risk of selection bias in this 
setting is negligible which contrasts studies including 
patients participating in clinical trials or patient series 
from single centers. We included the very old and frail 
patients and our study reflects the real- life population of 
multiple myeloma patients in Denmark. Consequently, the 
mortality of the elderly patients is higher than reported 
in most other studies [27–29]. Furthermore, the use of 
DNPR data ensures a complete nationwide ascertainment 
of former comorbid conditions in the myeloma patients 
and the comparison cohort. Despite these advantages, our 
registry- based study has some limitations. We had data 
on ISS stage in most patients, whereas cytogenetic and 
FISH only were performed in a limited number of the 
patients, in particular, in the early part of the inclusion 
period. Consequently, we were not able to include this 
important prognostic factor in our analysis of factors 
affecting mortality. The DNPR provides limited data on 
the severity and duration of the comorbid conditions and 
we were not able to validate the proposed Freiburg index. 
However, the positive predictive values in the DNPR of 
the diagnosis groups included in the Charlson Comorbidity 
Index are high (overall 98.0%) [30]. Diseases and com-
plications diagnosed in primary health care are not reg-
istered in the DNPR and this under- registration could 
diminish potential effects of specific conditions. Another 
concern is the risk of coding errors leading to misclas-
sification of comorbidity. However, this bias is likely to 
be similar in the myeloma patients and populations con-
trols at the time of interest and not subject to the sur-
veillance bias that might follow the diagnosis of multiple 
myeloma.
In conclusion, we found increased registration of 
comorbid disease within the year prior to diagnosis 
of multiple myeloma. This finding is likely to represent 
complications and morbidity secondary to yet undi-
agnosed multiple myeloma and also conditions related 
to the diagnostic process but it underlines the potential 
burden of comorbidity in myeloma. We found that 
comorbidity increased the mortality in multiple mye-
loma patients when we assessed the comorbidity in 
the Charlson Comorbidity Index as dichotomous vari-
ables, for example, no comorbidity versus any comor-
bidity or comorbidity score less than 2 compared with 
a score of 2 or higher which supported the use of the 
index in the IMWG frailty study. However, we did 
not find any clear difference in mortality between the 
subgroups 1, 2, and ≥3 according to Charlson 
Comorbidity Index.
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